Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-26
DOI
10.1186/s40425-019-0758-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibitors of the PD-1 Pathway in Tumor Therapy
- (2018) Martin W. LaFleur et al. JOURNAL OF IMMUNOLOGY
- TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways
- (2018) Chao Liang et al. Cell Death & Disease
- Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks
- (2018) Michael C. Comiskey et al. Current Oncology Reports
- Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
- (2018) Kazumi Ebine et al. Scientific Reports
- Immunotherapy for Prostate Cancer
- (2018) Nicholas J. Venturini et al. Cold Spring Harbor Perspectives in Medicine
- Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies
- (2017) Zoila Lopez-Bujanda et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model
- (2017) Ying-Chun Shen et al. PROSTATE CANCER AND PROSTATIC DISEASES
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
- (2017) Simon J. Hogg et al. Cell Reports
- Epigenetic Therapeutics: A New Weapon in the War Against Cancer
- (2016) Nita Ahuja et al. Annual Review of Medicine
- Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
- (2016) Maxim V. Kuleshov et al. NUCLEIC ACIDS RESEARCH
- Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
- (2016) E. S. Antonarakis et al. ONCOLOGIST
- Cancer immunotherapy targeting neoantigens
- (2016) Yong-Chen Lu et al. SEMINARS IN IMMUNOLOGY
- BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
- (2016) Hengrui Zhu et al. Cell Reports
- The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
- (2016) Alexander S. Baras et al. OncoImmunology
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- New Strategies in Bladder Cancer: A Second Coming for Immunotherapy
- (2015) A. Ghasemzadeh et al. CLINICAL CANCER RESEARCH
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?
- (2015) Byungsuk Kwon Immune Network
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
- (2014) Harm Westdorp et al. Frontiers in Immunology
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
- (2013) Edward Y Chen et al. BMC BIOINFORMATICS
- The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer
- (2013) Claudia C. Preston et al. PLoS One
- RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
- (2013) S. Picaud et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
- (2012) Anna Flammiger et al. EUROPEAN JOURNAL OF CANCER
- Immunotherapy earns its spot in the ranks of cancer therapy
- (2012) Drew Pardoll et al. JOURNAL OF EXPERIMENTAL MEDICINE
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
- (2010) Massimo Ammirante et al. NATURE
- Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer
- (2009) Barbara Seliger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More